HC Wainwright Has Bullish Estimate for SPRB FY2025 Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB) – HC Wainwright boosted their FY2025 earnings estimates for shares of Spruce Biosciences in a research note issued to investors on Thursday, February 19th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($55.59) per share for the year, up from their prior forecast of ($57.15). HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2025 earnings at ($13.73) EPS, Q1 2026 earnings at ($10.46) EPS, Q2 2026 earnings at ($9.38) EPS, Q4 2026 earnings at ($9.31) EPS and FY2026 earnings at ($38.23) EPS.

Several other research firms also recently weighed in on SPRB. Wall Street Zen downgraded Spruce Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Spruce Biosciences in a research note on Monday, December 29th. Leerink Partners raised shares of Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a research note on Wednesday, December 3rd. Citigroup restated a “market perform” rating on shares of Spruce Biosciences in a report on Tuesday, November 11th. Finally, Citizens Jmp set a $259.00 price target on shares of Spruce Biosciences in a research note on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $187.90.

Spruce Biosciences Price Performance

Shares of SPRB stock opened at $53.58 on Monday. The company has a market cap of $57.33 million, a PE ratio of -0.63 and a beta of 3.52. Spruce Biosciences has a 1 year low of $4.28 and a 1 year high of $240.00. The stock’s 50 day simple moving average is $77.01 and its two-hundred day simple moving average is $72.19.

Institutional Trading of Spruce Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Carlyle Group Inc. bought a new stake in Spruce Biosciences during the third quarter valued at about $24,765,000. Boothbay Fund Management LLC bought a new position in Spruce Biosciences in the fourth quarter worth about $4,175,000. Caligan Partners LP purchased a new stake in shares of Spruce Biosciences during the fourth quarter valued at about $1,787,000. ADAR1 Capital Management LLC bought a new stake in shares of Spruce Biosciences in the 4th quarter valued at about $5,052,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Spruce Biosciences in the 4th quarter worth approximately $2,157,000. Institutional investors own 91.71% of the company’s stock.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.